A novel drug and contrast agent targeting to brain acute ischemic stroke.
Project/Area Number |
26282139
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Biomedical engineering/Biomaterial science and engineering
|
Research Institution | Jikei University School of Medicine |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
SHIRAISHI Koichi 東京慈恵会医科大学, 医学部, 准教授 (40426284)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥15,860,000 (Direct Cost: ¥12,200,000、Indirect Cost: ¥3,660,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
Keywords | 急性期脳梗塞 / MRI / 造影剤 / 高分子ミセル / 高分子 / 脳保護薬 / ターゲティング / MRI / 高分子造影剤 / rt-PA / 脳神経疾患 / 高分子合成 / ナノバイオ / 医療・福祉 / 生理学 |
Outline of Final Research Achievements |
We aim to establish a proof of concept of novel targeting to acute brain ischemic stroke using macromolecular MRI contrast agents. We successfully prepared two types of contrast agents; polymeric micelle type and non-micelle forming type. Using these agents, we observed their significantly rapid accumulation at the ischemic sites in T1-weighted MR images. Owing to very distinct images with a long-time-lasting character, MRI analyses by the use of macromolecular contrast agents may realize risk prediction of brain hemorrhage induced by the t-PA therapy that is conducted against acute brain ischemic stroke.
|
Report
(4 results)
Research Products
(29 results)